Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: A randomized controlled trial

AIDS

Volumn 26, Issue 9, 2012, Pages 1105-1113

  Jarvis, Joseph N ^a,b,c   Meintjes, Graeme ^a,b,d   Rebe, Kevin ^b,e   Williams, Gertrude Ntombomzi ^b   Bicanic, Tihana ^c   Williams, Anthony ^f   Schutz, Charlotte ^a,b   Bekker, Linda Gail ^a   Wood, Robin ^a   Harrison, Thomas S ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b GF Jooste Hospital   (South Africa)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e ANOVA HEALTH INSTITUTE   (South Africa)

^f NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

cryptococcal meningitis; HIV; immunotherapy; interferon g; randomized controlled trial; South Africa

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; EFAVIRENZ; FLUCONAZOLE; FLUCYTOSINE; GAMMA1B INTERFERON; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIONEUROTIC EDEMA; ARTICLE; BRAIN INFARCTION; CEREBROSPINAL FLUID; COLONY FORMING UNIT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS; DIARRHEA; DISEASE ASSOCIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTERNAL OTITIS; FEMALE; FUNGICIDAL ACTIVITY; GASTROINTESTINAL HEMORRHAGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOTHERAPY; INTRACRANIAL PRESSURE; LACERATION; LEUKOPENIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NEUTROPENIA; PNEUMONIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCALP LACERATION; SEIZURE; SEPSIS; SIDE EFFECT; SODIUM BLOOD LEVEL; SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; VOMITING;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; CRYPTOCOCCUS NEOFORMANS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FEMALE; FLUCYTOSINE; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA; MALE; MENINGITIS, CRYPTOCOCCAL; TREATMENT OUTCOME;

EID: 84861529161     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283536a93     Document Type: Article

References (33)

1. Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS 2007; 21:2119-2129.
2. Jarvis JN, Boulle A, Loyse A, Bicanic T, Rebe K, Williams A, et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. Aids 2009; 23:1181-1185.
3. Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis 2010; 10:67.
4. Jarvis JN, Meintjes G, Harrison TS. Outcomes of cryptococcal meningitis in antiretroviral naive and experienced patients in South Africa. J Infect 2010; 60:496-498.
5. Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker LG, Harrison T. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45:76-80.
6. Bicanic T, Wood R, Meintjes G, Rebe K, Brouwer A, Loyse A, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008; 47:123-130.
7. Pappas PG, Bustamante B, Ticona E, Hamill RJ, Johnson PC, Reboli A, et al. Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004; 189:2185-2191.
8. Aguirre K, Havell EA, Gibson GW, Johnson LL. Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect Immun 1995; 63:1725-1731.
9. Kawakami K, Tohyama M, Teruya K, Kudeken N, Xie Q, Saito A. Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol Med Microbiol 1996; 13:123-130.
10. Kawakami K, Qureshi MH, Zhang T, Koguchi Y, Shibuya K, Naoe S, Saito A. Interferon-gamma (IFN-gamma)-dependent protection and synthesis of chemoattractants for mononuclear leucocytes caused by IL-12 in the lungs of mice infected with Cryptococcus neoformans. Clin Exp Immunol 1999; 117:113-122.
11. Uicker WC, Doyle HA, McCracken JP, Langlois M, Buchanan KL. Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococcus neoformans. Med Mycol 2005; 43:27-38.
12. Wormley FL Jr, Perfect JR, Steele C, Cox GM. Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect Immun 2007; 75:1453-1462.
13. Zhou Q, Gault RA, Kozel TR, Murphy WJ. Protection from direct cerebral cryptococcus infection by interferon-gammadependent activation of microglial cells. J Immunol 2007; 178:5753-5761.
14. Perfect JR, Granger DL, Durack DT. Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. J Infect Dis 1987; 156:316-323.
15. Joly V, Saint-Julien L, Carbon C, Yeni P. In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994; 170:1331-1334.
16. Siddiqui AA, Brouwer AE, Wuthiekanun V, Jaffar S, Shattock R, Irving D, et al. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol 2005; 174:1746-1750.
17. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, Harrison TS. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363:1764-1767.
18. National Antiretroviral Treatment Guidelines. National Department of Health South Africa; 2004.
19. Southern African HIV Clinicians Society. Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients. South Afr J HIV Med 2007; 28:25-35.
20. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 2010; 50:291-322.
21. NIH. Division of Aids Table for Grading the Severity of Adult and Pediatric Adverse Events. December 2004, Version 1.
22. Bicanic T, Muzoora C, Brouwer AE, Meintjes G, Longley N, Taseera K, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009; 49:702-709.
23. Bicanic T, Brouwer AE, Meintjes G, Rebe K, Limmathurotsakul D, Chierakul W, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 2009; 23:701-706.
24. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009; 48:856-862.
25. Jarvis JN, Lawn SD, Wood R, Harrison TS. Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action. Clin Infect Dis 2010; 51:1463-1465.
26. Jarvis JN, Meintjes G, Wood R, Harrison TS. Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme. AIDS 2010; 24:1233-1235.
27. Flesch IE, Schwamberger G, Kaufmann SH. Fungicidal activity of IFN-gamma-activated macrophages. Extracellular killing of Cryptococcus neoformans. J Immunol 1989; 142:3219-3224.
28. Voelz K, Lammas DA, May RC. Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect Immun 2009; 77:3450-3457.
29. Hardison SE, Ravi S, Wozniak KL, Young ML, Olszewski MA, Wormley FL Jr. Pulmonary infection with an interferongamma-producing Cryptococcus neoformans strain results in classical macrophage activation and protection. Am J Pathol 2010; 176:774-785.
30. Arora S, Hernandez Y, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle GB. Role of IFN-gamma in regulating T2 immunity and the development of alternatively activated macrophages during allergic bronchopulmonary mycosis. J Immunol 2005; 174:6346-6356.
31. Kawakami K, Qureshi MH, Zhang T, Okamura H, Kurimoto M, Saito A. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production. J Immunol 1997; 159:5528-5534.
32. Herring AC, Lee J, McDonald RA, Toews GB, Huffnagle GB. Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection. Infect Immun 2002; 70:2959-2964.
33. Aguirre K, Miller S. MHC class II-positive perivascular microglial cells mediate resistance to Cryptococcus neoformans brain infection. Glia 2002; 39:184-188.